Trial of add-on breast cancer treatment after surgery
Part of Cancer, Skin clinical trials.
This Phase 4 study tests an additional (adjuvant) treatment for breast cancer after surgery and standard follow-up care. It may help lower the chance the cancer comes back, but you must match specific tumor and body-chemistry requirements to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older, with breast cancer confirmed by biopsy or blood/tumor sample
- Your cancer is stage I to III and has not spread to distant organs (M0)
- Your ER, PR, HER2, and Ki-67 tumor tests are known, and your surgery was completed with no remaining visible tumor (R0)
- You can start the add-on treatment within 21 days after surgery, and you have not had paclitaxel before study entry
- You have adequate heart, liver, kidney, and blood counts, and you can do required checkups and lab tests
- If you could get pregnant, you must use reliable birth control and have a negative pregnancy test before starting treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This Phase 3 study tests giving trastuzumab and pertuzumab as additional (adjuvant) treatment after you had those same medicines before surgery but still had remaining cancer. It may help lower the chance that HER2-positive breast cancer comes back.
This study compares an “albumin-bound” form of paclitaxel versus other taxane chemotherapy options after breast surgery. It’s for people with HER2-negative, higher-risk breast cancer to see which approach works better in real-world care.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.